SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-022802-41

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate safety and tolerability of ODM-201 and to define dose(s) of ODM-201 for further clinical studies. Dose-limiting toxicities (DLT) and the MTD and/or OTD will be determined.


Critère d'inclusion

  • Progressive castration resistant prostate cancer (MedDRA: hormone-refractory prostate cancer)